Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 EUR | -4.57% | +7.74% | +56.07% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.07% | 163M | |
+23.37% | 47.02B | |
+49.79% | 41.86B | |
-0.94% | 41.76B | |
-4.27% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
+30.23% | 12.34B | |
-2.67% | 11.82B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics' Lung Cancer Vaccine Extends Survival in Late-stage Study